Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus.

ABSTRACT: Few studies were conducted to assess safety and efficacy of continuous antiviral therapy administrated from preconception. In the present study, 136 eligible women with chronic HBV infection were recruited, and assigned to active chronic hepatitis B (CHB) (Group A, B or C) or chronic HBV carrier (Group D). Antiviral therapy was administrated in preconception (Group A), in early (Group B) or late pregnancy (Group C and Group D). Immunoprophylaxis was administrated to all infants. Mothers' HBV status and ALT were assessed at delivery and 7 months postpartum. Offspring's HBV status was examined at 7 months old. Group A women showed low HBV DNA level and normal ALT throughout pregnancy. All women at delivery had an HBV DNA level of less than 10⁶ IU/ml, but the proportion of patients

SUBMITTER: Pan X 

PROVIDER: S-EPMC7423885 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature